Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 26, 2025
Daily News
February 26, 2025
- Lilly Japan Fostering Better Understanding of Health Issues to Retain Female Reps
February 26, 2025
- LDP, Komeito, Ishin Agree to Set Up Consultive Body for Social Security Reform
February 26, 2025
- Seikagaku Kicks Off Japan PIII for Osteoarthritis Drug Gel-One
February 26, 2025
- Japan Pharma Lobbies Likely to Enter Yasukawa/Miyabashira Era toward FY2026 Reform
February 26, 2025
- Shonan iPark to Drive Japan Approval of New Drugs from Korean Biotechs
February 26, 2025
- Coordinate Patent Issues with Originators before Listing: MHLW to Generic Firms
February 26, 2025
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…